MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

Dry eye is a common, painful ocular disturbance that can result from systemic inflammatory diseases, localized eye problems, or commonly used medications. Current treatments address symptoms, but a ...

Ever since the early use of cortisone for giant-cell arteritis in the 1950s,1 glucocorticoids have been a foundational treatment for this form of large-vessel vasculitis, providing clinical benefit ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in ...

An industry-supported center claims that it costs companies $2.6 billion to develop a new drug. But we need a broader-based and more transparent reckoning of research-and-development costs to infor ...

The landscape for genetically modified organisms is changing, thanks to sharp increases in the amounts and numbers of chemical herbicides applied to GM crops and the classification of two of the mo ...

The benefits of women’s health research haven’t been limited to women. But actions by the Trump administration threaten to dismantle the hard-won progress in this area.

Current international clinical practice guidelines recommend complete revascularization for patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease ...

An 83-year-old man presented with fatigue, weight loss, and postural hypotension. Computed tomography of the abdomen revealed marked enlargement of both adrenal glands, and a diagnosis of primary a ...

To the Editor: In their article on the PROPEL2 trial, Savarirayan and colleagues (Feb. 27 issue)1 describe the results of a phase 2 dose-finding trial of infigratinib in children with achondroplasi ...

On April 20, 2010, Arizona State University (ASU) agreed to pay $700,000 to 41 members of the Havasupai Indian tribe to settle legal claims that university researchers improperly used tribe members ...